RTTNews 汇总美股生物科技股当日涨幅，未给出新的未定价交易催化

Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
TODAY'S TOP STORIES
By
Prabha Kurup
✉
|
Published:
7/15/2026 11:41 PM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Today's biotech movers include Apollomics following its return to Nasdaq compliance, Iovance and AVITA ahead of Q2 earnings updates, Annexon, awaiting topline data in dry age-related macular degeneration with geographic atrophy, and Veradermics after reporting positive results from its female pattern hair loss trial.
Read on…
APLM Back on Track?
Apollomics Inc. (
APLM
) led the pack of gainers on Wednesday, with shares soaring more than 20%.
This clinical-stage company's lead program is Vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.
As recently as July 8, 2026, Apollomics was notified by Nasdaq that it had regained compliance with the Market Value of Listed Securities (MVLS) requirement under Listing Rule 5550(b)(2), and the matter has been closed.
APLM closed Wednesday's trading at $19.19, up 22.23%.
IOVA Gears Up for Q2 Results as Amtagvi Momentum Builds
Iovance Biotherapeutics Inc. (
IOVA
) jumped more than 20% on Wednesday, on no specific news.
This commercial biotechnology company focuses on developing and delivering novel polyclonal tumour-infiltrating lymphocyte (TIL) therapies for cancer. Its lead product Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication and is indicated for the treatment of adult patients with unresectable or metastatic melanoma.
The company is scheduled to report Q2, 2026 financial results during the first week of August.
U.S. Amtagvi revenue in Q2 2026 is expected to be $79 million to $81 million, which would be about 23% higher than in Q4 2025, the last quarter before scheduled iCTC maintenance. The maintenance temporarily reduced manufacturing capacity at the Iovance Cell Therapy Center, impacting Amtagvi production.
IOVA closed Wednesday's trading at $4.74, up 20.61%.
CNXU Hits Key Preclinical Milestone
Conexeu Sciences Inc. (
CNXU
), a preclinical-stage regenerative tissue platform company, was up more than 17% on Wednesday.
Recently, the company completed a 12-month preclinical P.R.O.O.F. study of its CXU platform, supporting its planned entry into the $11 billion medical aesthetics market. It intends to first seek FDA clearance through the predicate-based 510(k) pathway in wound care, which typically involves a 90-day FDA review rather than the multi-year studies required for a novel product category. The submission is planned for Q1 2027. This initial wound care clearance is expected to establish the regulatory foundation for the company's subsequent expansion into the medical aesthetics market.
CNXU closed Wednesday's trading at $11.18, up 17.68%.
Can RECELL Power AVITA's Growth?
AVITA Medical, Inc. (
RCEL
), a therapeutic acute wound care company, was up more than 17% on Wednesday.
The company is scheduled to report its second quarter 2026 financial results after the close of the U.S. financial
markets
on Thursday, August 6, 2026. Its flagship product is RECELL system, approved by the FDA for the treatment of thermal burn and trauma wounds.
In the first quarter of 2026, revenue was $19.3 million, and net loss was $10.6 million, or $0.35 per share. For the second quarter of 2025, the company reported revenue of $18.4 million and a net loss of $9.9 million, or $0.38 per share.
RCEL closed Wednesday's trading at $4.73, up 17.66%.
All Eyes on ARCHER II
Shares of Annexon Inc. (
ANNX
) jumped more than 17% on Wednesday, ahead of the presentation at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting on July 18, 2026.
The presentation, titled "Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy," will highlight baseline factors associated with vision loss in patients with geographic atrophy (GA) and inform patient selection for the ongoing Phase 3 ARCHER II trial.
The company expects to report topline pivotal data from the Phase 3 ARCHER II trial in the fourth quarter of 2026.
ANNX closed Wednesday's trading at $6.50, up 17.12%.
Adlai On Watch
Adlai Nortye (
ANL
), a global clinical-stage company at the forefront of discovering and developing innovative cancer therapies, was up 15% on Wednesday.
A Form 3 filing by Roger Sawhney on July 15, 2026, disclosed his initial beneficial ownership in the company as a director and 10% holder. The filing showed that Sawhney directly owns 9,838 ADSs and has indirect ownership of approximately 8,162 ADSs through restricted stock units (RSUs), which are scheduled to vest between August 2026 and August 2027.
ANL closed Wednesday's trading at $10.63, up 15.54%.
MANE Has a Good Hair Day
Veradermics Inc. (
MANE
) surged more than 12% on Wednesday, following positive topline results from its open-label Phase 2 clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss, dubbed Study '207.
According to the trial results, VDPHL01 demonstrated a rapid onset of hair growth, with most study participants reporting improved hair coverage as early as Month 2. By Month 6, approximately 88.9% of patients receiving once-daily dosing and 90.0% receiving twice-daily dosing reported their outcomes as "improved" or "much improved." The treatment also demonstrated robust hair growth, with mean increases in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² in the once-daily and twice-daily dosing groups, respectively.
A Phase 2/3 trial evaluating VDPHL01 in females with pattern hair loss, known as Study '306', is ongoing, with results to be announced in the first half of next year.
MANE closed Wednesday's trading at $123.70, up 12.28%.
Did you know?
A large multistate outbreak of cyclosporiasis is currently occurring in the U.S. According to the CDC, as of July 13, 2026, 1,645 laboratory-confirmed cases of cyclosporiasis have been reported among people who acquired the infection in the United States, spanning 34 states.
Cyclosporiasis is a gastrointestinal illness caused by the microscopic parasite Cyclospora. People become infected by consuming food or water contaminated with feces (stool) containing the parasite. Watery diarrhea is the most common symptom of cyclosporiasis.
If you experience symptoms of cyclosporiasis, contact your healthcare provider. The infection is typically treated with trimethoprim-sulfamethoxazole, an antibiotic sold under brand names including Bactrim, Septra, and Cotrim. People who are allergic to sulfa drugs should consult their healthcare provider about alternative treatment options. (Source: CDC)
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Biotech Stocks Facing FDA Decision In May 2026
Previous Story
Next Story
Latest Updates on Middle East War
U.S. Dollar Slides Amid Weaker-Than-Expected PPI Data
July 15, 2026 17:00 ET
Canadian Stocks Advance As Investors Parse BoC Monetary Policy Amid U.S.-Iran War
July 15, 2026 16:29 ET
Crude Oil Slips Amid EIA Data Release, Trump's Mixed Message To Iran
July 15, 2026 14:41 ET
Gold Slides Amid Concerns Of Expansive Gulf War, U.S. PPI Data Release
July 15, 2026 13:41 ET
Ships Stop Crossing Strait Of Hormuz As US-Iran Strikes Escalate
July 13, 2026 06:21 ET
View More
Global Economics Weekly Update - July 6 – July 10, 2026
July 13, 2026 10:12 ET
The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
View More Videos
RELATED NEWS
Veradermics Reports Positive Phase 2 Results For VDPHL01 In Women With Pattern Hair Loss; Stock Up
Veradermics Stock Surges 44% Over Positive Topline Data From Male Pattern Hair Loss Study
Veradermics' Oral VDPHL01 Shows Robust Hair Growth In Male Pattern Hair Loss Trial
Latest Updates on COVID-19
KFF Poll Finds AI Health Chatbot Users More Likely To Believe Vaccine Myths
July 01, 2026 14:27 ET
New Study Shows Updated COVID Vaccine Reduces Severe Illness And Hospitalizations
June 24, 2026 13:12 ET
Editor's Pick
Most Read
Most Emailed
Johnson & Johnson Lifts FY26 View, Despite Nearly Flat Q2 Profit; Stock Down
July 15, 2026 07:51 ET
Goldman Sachs Q2 Net Profit Nearly Doubles; Boosts Dividend 11% - Update
July 14, 2026 08:09 ET
JPMorgan Chase Q2 Profit, AUM Climb; But Shares Drop
July 14, 2026 07:27 ET
Bank Of America Q2 Net Profit Rises - Update
July 14, 2026 07:06 ET
Ericsson Stock Drops On Weak Q2, Cautious View On Q3 Networks Margin
July 14, 2026 06:15 ET
Holtec Nuclear Files For IPO On Nasdaq
July 11, 2026 01:58 ET
First Hawaiian To Acquire TriCo Bancshares In All-Stock Deal; Posts Preliminary Q2
July 13, 2026 07:50 ET
Delivery Hero Confirms Advanced Negotiations With Uber On Potential Acquisition Offer
July 15, 2026 02:05 ET
ABB Agrees To Buy Rotork In Deal With $5.5 Bln Enterprise Value
July 16, 2026 01:21 ET
First Bancorp To Acquire First Carolina In $166 Mln Stock-and-Cash Deal
July 14, 2026 09:28 ET
Barratt Redrow Sees FY26 Adjusted Pre-tax Profit In Line With View; Launches £386 Mln Share Buyback
July 15, 2026 02:52 ET
Diodes To Buy ElevATE Semiconductor For $250 Mln In Cash
July 14, 2026 09:13 ET
Citigroup Q2 Profit Climbs On Revenue Strength; But Shares Down - Update
July 14, 2026 08:59 ET
SGX Posts 31% Rise In June Derivatives Volume
July 13, 2026 01:39 ET
FDA Approves Merck's KEYTRUDA + Padcev Regimens For Muscle-Invasive Bladder Cancer
July 11, 2026 01:21 ET
Apple Sues Former Employees And OpenAI Over Trade Secret Theft
July 11, 2026 03:17 ET
Renault Group Wins High Court Ruling In London Diesel Emissions Case
July 11, 2026 02:23 ET
Kaneko Seeds Co Ltd Full Year Profit Advances
July 13, 2026 01:25 ET
Takeda And Indonesia Announce Plasma Collaboration To Build ASEAN's First Regional Hub
July 12, 2026 21:05 ET
Unifor Reaches Tentative Agreement With Ford For 5,150 Canadian Workers
July 12, 2026 21:55 ET
Gjensidige Q2 Profit From Cont. Ops. Declines
July 13, 2026 02:01 ET
ASIC: Deutsche Bank Pays A$2 Mln Penalty For Systemic Trade Reporting Failures
July 13, 2026 01:15 ET
Astena Holdings Co.,Ltd. Announces Climb In H1 Profit
July 13, 2026 02:14 ET
Amended: Gjensidige Forsikring ASA Q2 Profit Drops
July 13, 2026 01:28 ET
Editors Pick
Delta Air Lines Q2 Profit Declines; Affirms FY26 Outlook
July 10, 2026 08:14 ET
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
.
About Us
Privacy
Sitemap